UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

DUPILUMAB IS EFFECTIVE IN TREATING EOE REGARDLESS OF BASELINE WEIGHT OR BMI: POOLED RESULTS FROM PART A AND PART B OF THE LIBERTY EOE TREET STUDY

Ikuo Hirano 1, Mirna Chehade 2, Evan S. Dellon 3, Alain M. Schoepfer 4, Changming Xia 5, Arsalan Shabbir 5, Lila Glotfelty 6

Affiliations

1 Northwestern University Feinberg School of Medicine, Chicago, United States

2 Icahn School of Medicine at Mount Sinai, New York, United States

3 University of North Carolina School of Medicine, Chapel Hill, United States

4 Université de Lausanne, Lausanne, Switzerland

5 Regeneron Pharmaceuticals Inc., Tarrytown, United States

6 Sanofi, Bridgewater, United States

Summary

AI Generated

Post hoc analysis of the Phase 3 LIBERTY EoE TREET study demonstrates dupilumab 300 mg weekly improved histologic, symptomatic, and endoscopic outcomes in eosinophilic esophagitis at 24 weeks regardless of baseline patient weight or body mass index.

In 240 patients from pooled Parts A and B, dupilumab significantly increased the proportion achieving peak esophageal eosinophil count ≤6 eos/hpf at week 24 versus placebo across weight subgroups (weight <60kg: 47% vs 5%, p=0.0031; weight ≥60kg: 63% vs 6%, p<0.0001) and BMI subgroups (BMI <25kg/m²: 56.3% vs 3.5%; BMI ≥25–<30kg/m²: 61.1% vs 5.4%; BMI ≥30kg/m²: 63.6% vs 12.5%).
Dupilumab reduced DSQ scores, EREFS total scores, and HSS grade and stage scores at week 24 compared with placebo across all weight and BMI subgroups, with most comparisons reaching statistical significance.
A greater proportion of dupilumab-treated patients achieved peak eosinophil count <15 eos/hpf versus placebo in all subgroups (weight <60kg: 70% vs 10%, p=0.0006; weight ≥60kg: 78% vs 7%, p<0.0001; similar results across BMI categories).
Dupilumab was well tolerated with a safety profile similar to the overall treatment population; baseline demographics and disease characteristics were generally similar across weight and BMI subgroups in this post hoc analysis with nominal p-values.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease with substantial impact on quality of life, and increasing incidence and prevalence. Dupilumab, a fully human monoclonal antibody, blocks IL-4 and IL-13, central drivers of type 2 inflammation, and is approved in the US and EU for the treatment of EoE.

Aims & Methods

We aimed to assess the effect of dupilumab on EoE outcomes in subgroups of patients from the Phase 3 LIBERTY EoE TREET (NCT03633617) study categorized by weight or body mass index (BMI).
Data were pooled from patients in Parts A and B who received dupilumab 300 mg or placebo qw (weekly) for 24 weeks (W24). The proportion of patients achieving ≤6 or <15 eosinophils per high-power field (eos/hpf), absolute change in Dysphagia Symptom Questionnaire (DSQ) score, mean change in Endoscopic Reference Score (EREFS), and Histologic Scoring System (HSS) grade/stage scores were assessed. Outcomes were compared between pre-specified weight (<60kg and ≥60kg) and BMI groups (<25kg/m², ≥25–<30kg/m², and ≥30kg/m²). As this is a post hoc analysis, all p-values are nominal.

Results

122 patients received dupilumab and 118 placebo. At baseline, subgroups comprised: Weight <60kg (N=51) and ≥60kg (N=189); BMI <25kg/m² (N=121), ≥25–<30kg/m² (N=73), and ≥30kg/m² (N=46). Baseline demographics and disease characteristics were generally similar across subgroups. Dupilumab was efficacious regardless of baseline weight. At W24 dupilumab treatment resulted in a greater proportion of patients achieving ≤6 eos/hpf compared with placebo (weight <60kg 47% vs 5%, p=0.0031, ≥60kg 63% vs 6%, p<0.0001), and improved DSQ score (LS mean difference [LSMD] [95% CI]: weight <60kg –8.74 [–18.77, 1.30], p=0.0878, ≥60kg –10.36 [–14.57, –6.15], p<0.0001). Dupilumab-treated patients improved at W24 vs placebo in EREFS total score (LSMD [95% CI]: –2.47 [–3.89, –1.06], p=0.0006, –3.66 [–4.50, –2.81], p<0.0001), and HSS mean grade (–0.608 [–0.837, –0.380], p<0.0001, –0.737 [–0.839, –0.636], p<0.0001) and stage scores (–0.588 [–0.811, –0.365], p<0.0001, –0.730 [–0.826, –0.633], p<0.0001). Furthermore, dupilumab treatment resulted in a greater proportion of patients achieving <15 eos/hpf compared with placebo (weight <60kg 70% vs 10%, p=0.0006, ≥60kg 78% vs 7%, p<0.0001). Similar results were observed across BMI subgroups (Table).

Table: EoE endpoints in patients categorized by weight or BMI at Week 24

	Weight <60kg		Weight ≥60kg		BMI <25kg/m²		BMI ≥25–<30kg/m²		BMI ≥30kg/m²
Endpoint (95% CI)	PBO N=21	DUP N=30	PBO N=97	DUP N=92	PBO N=57	DUP N=64	PBO N=37	DUP N=36	PBO N=24	DUP N=22
% pts with peak eosinophil count ≤6 eos/hpf	4.8 (0.1, 23.8)	46.7 (28.3, 65.7)	6.2 (2.3, 13.0)	63.0 (52.3, 72.9)	3.5 (0.4, 12.1)	56.3 (43.3, 68.6)	5.4 (0.7, 18.2)	61.1 (43.5, 76.9)	12.5 (2.7, 32.4)	63.6 (40.7, 82.8)
LS mean change from baseline in DSQ score	–18.0 (–26.6, –9.4)	–26.7 (–33.6, –19.9)	–10.8 (–14.5, –7.2)	–21.2 (–24.8, –17.6)	–15.0 (–19.5, –10.4)	–22.8 (–27.0, –18.7)	–11.0 (–16.7, –5.4)	–21.1 (–27.1, –15.0)	–5.2 (–14.7, 4.4)	–19.1 (–28.8, –9.5)
LS mean change from baseline in EREFS total score	–1.75 (–2.95, –0.55)	–4.22 (–5.26, –3.19)	–0.25 (–1.00, 0.49)	–3.91 (–4.64, –3.18)	–0.37 (–1.18, 0.44)	–4.19 (–4.99, –3.39)	–0.56 (–1.59, 0.46)	–3.92 (–5.01, –2.84)	–0.31 (–2.78, 2.15)	–3.23 (–5.68, –0.77)
LS mean change from baseline in HSS mean grade score	–0.207 (–0.400, –0.013)	–0.815 (–0.976, –0.654)	–0.053 (–0.142, 0.037)	–0.790 (–0.877, –0.703)	–0.109 (–0.209, –0.010)	–0.848 (–0.946, –0.749)	–0.124 (–0.262, 0.014)	–0.771 (–0.917, –0.625)	0.055 (–0.228, 0.337)	–0.674 (–0.950, –0.397)
LS mean change from baseline in HSS mean stage score	–0.192 (–0.383, –0.002)	–0.780 (–0.939, –0.622)	–0.034 (–0.120, 0.051)	–0.764 (–0.848, –0.681)	–0.100 (–0.199, –0.001)	–0.811 (–0.909, –0.714)	–0.075 (–0.203, 0.054)	–0.721 (–0.858, –0.584)	0.061 (–0.195, 0.316)	–0.658 (–0.907, –0.410)
% pts with peak eosinophil count <15 eos/hpf	9.5 (1.2, 30.4)	70.0 (50.6, 85.3)	7.2 (3.0, 14.3)	78.3 (68.4, 86.2)	7.0 (2.0, 17.0)	76.6 (64.3, 86.3)	5.4 (0.7, 18.2)	72.2 (54.8, 85.8)	12.5 (2.7, 32.4)	81.8 (59.7, 94.8)

BMI, body mass index; CI, confidence interval; DSQ, Dysphagia Symptom Questionnaire; DUP, dupilumab; EREFS, Endoscopic Reference Score; eos, eosinophils; hpf, high-powered field; HSS, Histologic Scoring System; LS, least squares; PBO, placebo; pts, patients.

Conclusion

Patients with EoE improved in measures of histology, symptoms, and endoscopy, including an increased proportion achieving peak esophageal intraepithelial eosinophil count ≤6 and <15, along with reductions in DSQ score, HSS grade and stage scores, and EREFS total score at W24 with dupilumab 300 mg qw vs placebo regardless of baseline weight or BMI. Dupilumab was well tolerated, and the safety profile was similar to the overall treatment population.

Disclosure

Hirano I: Allakos, Pfizer/Arena Pharmaceuticals, Aslan, AstraZeneca, Calyx/Parexel, Ellodi/Adare Pharma Solutions, EsoCap, Gossamer Bio, Phathom, Nexstone Immunology, Receptos/BMS, Sanofi/Regeneron Pharmaceuticals Inc., Shire/Takeda – consultant; Adare Pharma Solution, Allakos, AstraZeneca, Pfizer/Arena, Meritage Pharma, Receptos/BMS, Regeneron Pharmaceuticals Inc., Shire/Takeda – research funding; Sanofi/Regeneron Pharmaceuticals Inc. – speaking.
Chehade M: Adare Pharma Solutions, Allakos, AstraZeneca, BMS, Phathom, Recludix Pharma, Regeneron Pharmaceuticals Inc., Sanofi, Shire/Takeda – consultant; Adare Pharma Solutions/Ellodi Pharmaceuticals, Allakos, AstraZeneca, Danone, Regeneron Pharmaceuticals Inc., Shire/Takeda – research funding.
Dellon ES: Abbott, AbbVie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron Pharmaceuticals Inc., Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio– consultant; Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron Pharmaceuticals Inc., Revolo, Shire/Takeda – research funding; Allakos, Holoclara, Invea– educational grant.
Schoepfer AM: Adare Pharma Solutions, Aptalis, Dr. Falk – consultant; AstraZeneca, Aptalis, Dr. Falk, GSK, Nestlé, Novartis, Receptos/BMS, Regeneron Pharmaceuticals Inc. – research funding.
Xia C, Shabbir A: Regeneron Pharmaceuticals Inc. – employees and shareholders.
Glotfelty L: Sanofi – employees, may hold stock and/or stock options in the company.

Conference

UEG Week Copenhagen 2023

Topics

Oesophagus

Submission format

Abstract

Session

All about EoE (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

DEFINING THE OPTIMAL STRATEGY FOR PROTON PUMP INHIBITOR DEPRESCRIBING: RESULTS FROM THE PEPPER TRIAL

Florencia Carbone

A primer in capsule endoscopy

Uwe Seitz

MUFEMILAST (ORAL PDE4B SELECTIVE EXPRESSION INHIBITOR) FOR ULCERATIVE COLITIS: OPEN-LABEL EXTENSION RESULTS AT 24 WEEKS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP INDUCTION PHASE II CLINICAL TRIAL

Xiuli Zuo

Clinical introduction to colorectal polyps

Tomer Adar

EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF 2,254 EMPIRICAL RESCUE THERAPIES ON THIRD AND SUBSEQUENT LINES

Samuel Jesús Martínez-Domínguez

ADHERENCE TO THE MEDITERRANEAN DIET AND VISCERAL ADIPOSITY PREDICTS GASTROINTESTINAL CANCER DEVELOPMENT IN METABOLIC SUBJECTS

LUCILLA CRUDELE

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

DEFINING THE OPTIMAL STRATEGY FOR PROTON PUMP INHIBITOR DEPRESCRIBING: RESULTS FROM THE PEPPER TRIAL

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.